AGC Biologics Building New ATMP and Mammalian Facility in Japan 05 January 2024
Today we are pleased to share construction plans for a new manufacturing facility at AGC Inc.’s Yokohama... Read more
Today we are pleased to share construction plans for a new manufacturing facility at AGC Inc.’s Yokohama... Read more
COPENHAGEN, DENMARK AND CAMBRIDGE, MASS., US – January 4, 2024 – Hemab Therapeutics, a clinical-stage... Read more
NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
Today, Gubra announces the signing of a new research and license agreement with Boehringer Ingelheim... Read more
NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
Q3 2023 DANYELZA® net product revenues of $20.0 million represents YoY growth of 59% U.S. FDA clearance... Read more
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
NEW YORK, Oct. 18, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
Clearance of CD38-SADA IND marks the second clinical development program utilizing the Company’s novel... Read more